Last reviewed · How we verify
PF-07275315-dose 3 (pf-07275315-dose-3)
PF-07275315-dose 3 is a marketed drug by Pfizer Inc. for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Mantle Cell Lymphoma, Relapsed or Refractory Marginal Zone Lymphoma, and Relapsed or Refractory Follicular Lymphoma. The mechanism of action is not specified. PF-07275315-dose 3 has generated $7 mn in revenue. It is a small molecule drug. The drug's clinical differentiation and commercial significance are not well-documented. There are no pipeline developments available. The drug is not mentioned on Wikipedia.
At a glance
| Generic name | pf-07275315-dose-3 |
|---|---|
| Sponsor | Pfizer |
| Drug class | small molecule |
| Target | unknown |
| Phase | FDA-approved |
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Mantle Cell Lymphoma
- Relapsed or Refractory Marginal Zone Lymphoma
- Relapsed or Refractory Follicular Lymphoma
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- Relapsed or Refractory Waldenström's Macroglobulinemia
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Relapsed or Refractory Hairy Cell Leukemia
- Relapsed or Refractory Myeloproliferative Neoplasm
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C9 inhibitors
- CYP2C9 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07275315-dose 3 CI brief — competitive landscape report
- PF-07275315-dose 3 updates RSS · CI watch RSS
- Pfizer portfolio CI